At Cleveland Clinic, we welcome change, encourage invention and continually seek better, more efficient ways to achieve our goals.
From pill-sized cameras to radioactive compounds that let doctors “see” inside a patient’s brain, Cleveland Clinic’s Top 10 Medical Innovations for 2011 showcases new techniques, therapies and approaches to treating a host of diseases. The list of breakthrough devices and therapies was compiled by a panel of Cleveland Clinic physicians and scientists and unveiled recently during Cleveland Clinic’s 2010 Medical Innovation Summit.
The Top 10 Medical Innovations for 2011
10. Capsule endoscopy for diagnosis of pediatric GI disorders: A pill-sized camera captures 50,000 high-resolution images during its painless six- to eight-hour journey through the digestive tract, proving better than x-rays at detecting small bowel ulcerations, polyps and areas of bleeding.
9. Oral disease-modifying treatment for multiple sclerosis: Before fingolimod was approved by the FDA this year, MS drugs had to be injected or infused on a regular basis. This oral medication effectively stops T-cells from attacking the myelin sheaths that cover nerve fibres.
8. Exhaled nitric oxide (NO) breath analysis for diagnosing asthma: A new hand-held diagnostic testing device measures a patient’s level of exhaled NO, which is a biomarker for asthma. Monitoring NO levels allows doctors to more accurately tailor treatment strategies.
7. Transoral gastroplasty (TOGA): A new experimental weight-loss option for obese patients who want to lose weight and improve their health without undergoing major surgery. This “scar-less” procedure represents a significant improvement in minimally-invasive bariatric surgery and losses approaching 40 percent of excess body weight can be expected within a year.
6. Telehealth monitoring for heart failure patients: Miniature implantable monitors that measure pulmonary artery pressure daily and other at-home devices that monitor weight, heart rate and blood pressure of heart failure patients allow doctors to adjust medication quickly, improving patient outcomes and quality of life while reducing rehospitalizations.
5. Hepatitis C protease-inhibiting drugs: Two drugs awaiting FDA approval treat hepatitis C using protease inhibitors, which work by blocking a key enzyme that viruses need to copy themselves and proliferate. In clinical trials, cure rates for the protease inhibitors are higher than current hepatitis C treatments, with fewer side effects.
4. JUPITER study and statins for healthy individuals: The JUPITER (Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin) trial pointed out for the first time that many seemingly healthy people are at higher risk of heart disease than previously thought, suggesting that statins should be prescribed even to people with low LDL (bad cholesterol), if they have high C-reactive protein levels.
3. First therapeutic cancer vaccine approved by the FDA: While not a cure for prostate cancer, sipuleucel-T is the first cancer vaccine to receive FDA approval. Prescribed to men with advanced prostate cancer, the drug coaxes their own immune systems into attacking and removing the cancer, reducing the risk of death by 24 percent compared to placebo.
2. Anti-CTLA-4 drug (ipilimumab), a T-cell antibody targeting metastatic melanoma: The effectiveness of ipilimumab in treating melanoma confirms immunotherapy as an effective treatment. In patients with advanced stage III or IV melanoma, 23 percent were still alive after two years compared to 14 percent of patients who received standard treatment.
1. New molecular imaging biomarker for early detection of Alzheimer’s disease: Currently, positive diagnosis of Alzheimer’s is possible only upon autopsy. But a radioactive molecular imaging compound called AV-45 and a PET scan can allow doctors to “see” inside patients’ brains to detect beta-amyloid plaques, the telltale signature of Alzheimer’s.
How were the innovations selected?
Four major criteria served as the basis for qualifying and selecting the Top 10 Medical Innovations for 2011. Nominated innovations were required to:
- Have significant potential for short-term clinical impact (either a major improvement in patient benefit or an improved function that enhances healthcare delivery)
- Have a high probability of success
- Be on the market or close to being introduced
- Have sufficient data available to support the nomination